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Abstract 
Several studies have shown that symptomatic toxicities associated with anti-cancer 
treatments, such as nausea and vomiting, are frequently under-reported by health care 
providers, even when prospectively collected within clinical trials. Such under-reporting 
can produce underestimation of the absolute rate of toxicity, which is highly relevant 
information for patients and their physicians in clinical practice, as well as for regulatory 
authorities. Systematic collection of patient-reported outcomes (PROs) has been 
demonstrated to be a valid, reliable, feasible, and more precise approach to tabulating 
symptomatic toxicities, compared to health care provider reporting. The U.S. National 
Cancer Institute has developed a PRO version of the Common Terminology Criteria for 
Adverse Events (the “PRO-CTCAE”) to improve toxicity measurement in clinical trials. The 
PRO-CTCAE is an item bank with 124 individually validated toxicity questions for patients, 
with an accompanying software system for directly collecting information about 
symptomatic adverse events from patients. The barriers and challenges that need to be 
addressed when considering broad integration of PRO toxicity monitoring in cancer clinical 
trials are discussed, including challenges related to data collection logistics, analytic 
approaches, and resource utilization. The advent of instruments like the PRO-CTCAE, 
conceived to describe therapy side effects from the patient perspective, brings the 
potential both to improve the quality of data for risk-benefit evaluation in clinical research, 
and to provide future patients facing treatment decisions with information about prior 
experiences of their peers.  
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Introduction. 
  Knowledge regarding potential benefits and risks associated with anticancer therapies 
is fundamental for making treatment-related recommendations and decisions. This 
information is key for multiple stakeholders, including regulatory authorities, clinical 
researchers, physicians, and not least of all for patients. In the regulatory process for the 
authorization of new medicinal products, both the Food and Drug Administration (FDA) [1] 
and the European Medicines Agency (EMA) [2] have frameworks for conducting benefit / 
risk evaluation that rely on qualitative analysis and judgment by experts regarding the 
available clinical data, classically (but not necessarily) obtained from randomized 
controlled clinical trials. Benefit is measured in terms of therapeutic efficacy, evaluated 
according to the primary endpoints for which the studies were designed and powered, 
such as overall survival or progression free-survival [3]. On the other hand, risk 
assessment, with evaluation of potential harm from anti-cancer therapy, is based largely 
on toxicity information garnered in the trials, for which the mainstay has been the 
investigator reporting of adverse events according to the Common Terminology Criteria for 
Adverse Events (CTCAE) [4]. The CTCAE defines individual adverse event terms and 
provides a grading scale for severity of each item. Some adverse events may be 
measureable in terms of laboratory and other exams (e.g. anemia, QT prolongation), and 
others from direct clinician observation or measurement (e.g. maculo-papular rash, 
hypertension). However, approximately 10% of the adverse event items in the CTCAE 
represent symptomatic toxicities that, in order to be reported, require that the clinician 
elicits and then grades the subjective experiences of the patient (diarrhea, fatigue, pain). 
This system is at risk of underestimating subjective toxicities for several reasons, related to 
physicians’ performance or to more complex aspects of interaction and communication 
between physicians and patients. Further, this indirect method of reporting a patient 
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symptom is at risk for errors in interpretation along the way to  final codification as a 
graded CTCAE in the clinical trial database. By definition of the FDA, clinician reported 
outcomes “involve  clinical judgment or interpretation of the observable signs, behaviors, 
or other physical manifestations thought to be related to a disease or condition, and cannot 
directly assess  symptoms that are known only to the patient”  
(http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualifica
tionProgram/ucm370262.htm).   
Healthcare provider reporting via the CTCAE has been demonstrated to have a low 
level of inter-rater reliability [5], and to miss up to half of patients’ symptoms compared to 
direct accounts from patients themselves [6]. Moreover, compared to patient reports, 
healthcare professional toxicity reports are less concordant with global health status [7].  
Of course, as described elsewhere, not all toxicities are amenable to patient reporting [8].  
In fact, as noted by the FDA [9], subjective experiences such as symptoms are best known 
by patients and therefore are those optimally reported directly by patients without filtering 
by a healthcare professional.  On the contrary, non-subjective toxicities such as laboratory 
test-based toxicities (e.g., neutropenia), or observable phenomena (e.g., retinal 
detachment), are best reported by providers. 
Over the past decade, interest has grown in the potential integration of patient-reported 
outcomes (PROs) as part of routine toxicity data collection and reporting in clinical trials 
[6,10]. A PRO is defined as a measurement about the patient’s condition, reported directly 
from the patient, without interpretation by clinician or anyone else. Symptom items in 
quality of life (QOL) instruments, validated symptom scales, and more recently a patient 
reported outcomes version of the CTCAE developed by the U.S. National Cancer Institute 
provide means for collecting unfiltered information about symptomatic toxicities directly 
from patients [11].  
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The FDA and EMA have provided guidance on the use of PROs in clinical trials [9,12], 
and EMA specifically in trials of anticancer drugs [13], further underlining the importance of 
including the patient’s perspective as a standard and essential source of information when 
evaluating benefits and harms of cancer therapeutics. Of note, FDA advocates that 
symptoms or other unobservable concepts known only to the patient (e.g., nausea or pain 
severity) can adequately be measured only by PRO measures. Patient-reported toxicities 
may have particular value in trials of oral cancer therapies, where outpatient compliance is 
a known issue; understanding symptomatic toxicities early in development may be useful, 
because it is known that patients might discontinue medicines with bothersome 
symptomatic toxicities (e.g., discontinuation of aromatase inhibitors due to arthralgias).  
Patient reports may also be especially useful in precision medicine and first-in-man trials, 
where there are limited insights about impact on patients, for example with immune 
therapies, which have non negligible - and sometimes unpredictable - toxicities.  
 
Agreement between patients and physicians 
The report by cancer patients themselves is widely considered the gold standard for 
the assessment of symptoms, as patients are in the best position to comment on their own 
subjective experiences [9,12]. Published studies have consistently demonstrated that 
health professionals underestimate the incidence and severity of symptoms, when 
compared with the report by patients [14-17]. More specifically, a number of publications 
have been focused on the comparison between patients’ and physicians’ reporting of 
treatment adverse events experienced by cancer patients, allowing the description of 
under-reporting by physicians [18-21].  
A structured literature review was conducted via Medline including papers published 
through August 24, 2015 with the search terms (patient OR patients) AND (physician* OR 
clinician* OR investigator* OR nurse*) AND cancer AND (report* OR agreement OR 
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comparison OR assessment OR evaluation) AND (toxicity OR symptom* OR tolerance OR 
tolerability), restricting the search strategy to adult patients. Reference lists of selected  
publications were also reviewed. Of note, the adoption of literature search criteria with 
reasonable specificity and enough sensitivity to identify all the existing studies describing 
any form of comparison between patients’ and physicians’ assessment of toxicity or 
symptoms is particularly difficult. However, a systematic description of all the existing 
publications goes beyond the scope of this article, because our aim is to give the readers a 
convincing evidence of the relevance of under-reporting by health professionals. The main 
characteristics (aim of the study, setting, number of patients and institutions, instruments 
used for patients’ reporting and health professionals’ reporting) and the most relevant 
results of selected studies comparing report by patients and health care professionals of 
toxicity or symptoms associated with anti-cancer treatment are summarized in Table 1. 
Although it is recognized that this may not be an exhaustive list, these papers are 
representative of the overall literature in this area.  
Overall, across studies it was found that clinicians consistently and substantially 
under-report both the prevalence and severity of patients’ symptoms compared to the 
direct reports from patients themselves.  For example, Fromme and colleagues reported 
that physicians’ evaluation of toxicity was inaccurate, when compared to patients’ self-
reporting, even in the controlled setting of a prospective trial [18]. Those authors analyzed 
data collected in a prospective clinical trial evaluating weekly calcitriol and docetaxel in 
patients with metastatic androgen-independent prostate cancer. The authors found that 
that physician reporting was neither sensitive nor specific in detecting common 
chemotherapy adverse effects, with a Cohen’s kappa coefficient as low as 0.15, indicating 
a poor agreement.  
In that study by Fromme and colleagues, comparison between patients’ and 
physicians’ reporting was based on different instruments. However, even in the several 
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studies where comparison between patients’ and physicians’ reporting has been assessed 
using the same instrument, results have underlined the risk of under-reporting by 
physicians. For example, Basch and colleagues prospectively compared reporting of 
symptom occurrence and severity by cancer patients and clinicians among outpatients 
with lung and genitourinary cancer [19]. Both patients’ and clinicians’ reports were based 
on the CTCAE; the only difference was that items were transcribed unchanged in the 
questionnaire filled-in by clinicians, while the patient version included identical items with 
syntactical modifications in order to improve comprehension. For symptoms that can be 
better “quantified”, such as vomiting or diarrhea, agreement was relatively high. However, 
agreement was low for subjective symptoms such as fatigue and dyspnoea. In a similar 
study performed in Italy among outpatients undergoing chemotherapy [20], agreement 
between patients and nurses was generally stronger than those between patients and 
physicians. Based on these results, the authors suggested that the nurses could be 
successfully employed in collecting treatment toxicity, because they showed a better 
performance than doctors in reporting information from the patients.  
However, given the prospective design of these latter comparisons, it is worth 
noting that healthcare professionals, although blinded to patients’ answers, were aware 
that their report would have been subsequently compared with patients’ report; it is 
reasonable that the rate of under-reporting by clinicians, when they are not aware of the 
comparison with patients’ report, could be substantially higher. In a recent pooled analysis 
of three randomized trials, patients’ and clinicians’ reporting of six toxicities (anorexia, 
nausea, vomiting, constipation, diarrhea, and hair loss) experienced during anti-cancer 
treatment were subsequently compared [21]. Agreement between patients and clinicians 
was low, and toxicity rates based on physicians’ report were consistently lower than those 
reported by patients themselves. Under-reporting by clinicians ranged from 41% for 
nausea to 74% for appetite loss.  
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Although a systematic description of the factors potentially explaining the under-
reporting of treatment toxicities by health professionals is not available in literature, we 
listed and commented the most relevant factors in Table 2. Factors are divided in two 
large groups: in the first group, information about toxicity is correctly acquired but not 
reported, while in the second group the under-reporting is the consequence of a defect in 
communication between patients and health professionals. 
In some cases, information about treatment toxicity, although not explicitly reported, 
could have been correctly acquired by health professionals. They could decide not to 
report the symptoms that were already present before treatment start, or those judged 
unrelated to treatment but related to previous treatments or to the disease itself. This could 
be true for some adverse events: for instance, fatigue or appetite loss are commonly 
related to cancer itself, at least in patients with advanced disease; on the other hand, 
peripheral neurotoxicity or hair loss could be expression of residual toxicity from previous 
treatment lines. However, this explanation is far less reasonable for many adverse events, 
like nausea or vomiting or diarrhea, that could be prudently considered treatment-related in 
the majority of cases. 
Physicians might also pay less attention in reporting mild toxicities, particularly 
those effects that would not prompt treatment modification or supportive care. However, an 
accurate evaluation of the risk / benefit ratio of a treatment should be based on a complete 
reporting of toxicities, including also mild grades, particularly if long-lasting. Furthermore, 
there are data suggesting that under-reporting can occur even when patients describe 
severe toxicity [21]. In a previously described study, the analysis limited to patients who 
reported “very much” toxicity in any cycle, showed that the proportion of under-reporting by 
physicians was lower, as expected, compared to the analysis of “any grade” toxicity, but 
was relevant in any case, ranging from 13.0% for vomiting to 50.0% for anorexia (Figure 
1) [21].  
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In other cases (lower half of Table 2), under-reporting could be due to a defect in 
communication between patients and health professionals, with the latter not acquiring at 
all the proper information about the occurrence of toxicity. In this case, under-reporting 
could lead to a risk of sub-optimal management of the symptoms. If a specific toxicity is 
largely expected with the drug that the patient is receiving, physicians could “paradoxically” 
pay less attention to its meticulous report. However, at least in principle, also the opposite 
could be true, because clinicians could be more accurate in asking patients about largely 
expected toxicities. From this point of view, it is interesting that in the TORCH trial, 
comparing erlotinib versus cisplatin + gemcitabine as first-line treatment of patients with 
advanced non-small-cell lung cancer, the rate of under-reporting for nausea, vomiting and 
diarrhea suggests that physicians are more accurate in reporting those side effects that 
are expected with each specific treatment (Figure 2) [21]. In detail, the under-reporting of 
nausea and vomiting was higher with erlotinib than with chemotherapy, that indeed is 
expected to produce more emesis than erlotinib. On the other hand, the under-reporting of 
diarrhea was higher with cisplatin + gemcitabine than with erlotinib, that is typically 
expected to produce more diarrhea than chemotherapy.  
Table 2 describes also potential implications for clinical management. If physicians 
correctly acquire information about a toxicity but simply under-document, the implication 
for clinical management may be minimal, but there are substantial implications for clinical 
trial tabulation. Under-reporting of toxicities in clinical trials and resulting publications and 
drug labels may lead to subsequent patients under-appreciating the impact a product may 
have on them. Moreover, there is a lost opportunity for adverse event management 
programs, and compliance may be negatively affected. In contrast, if under-reporting is 
due to under-detection, for example due to communication barriers between patients and 
clinicians, it may lead to the risk of both sub-optimal toxicity management and sub-optimal 
tabulation.  
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Incorporation of PROs in toxicity description  
Several barriers exist to integrating PROs into routine toxicity collection in cancer 
clinical trials, and solutions have been suggested and tested [6,8]. In terms of data 
collection, concerns have been raised that completion rates may be low, particularly from 
ill or end-stage patients. Feasibility assessments embedded in multiple clinical trials have 
now demonstrated sustained compliance rates of approximately 90% during active 
therapy, including those with impaired performance status [22-24]. Response rates from 
patients can be optimized through a number of approaches [25]. First, patients are more 
likely to respond if they know this is an important part of a trial, that the PROs are 
requested by their doctor and nurse, and that the information will benefit future patients 
[25].  This message can be conveyed during informed consent and PRO training. Second, 
questionnaires need to be brief and easy to complete. Third, compliance should be 
monitored in real-time, with human backup data collection for non-responders, for example 
via a telephone call. Backup data collection improves compliance rates by about 10% 
overall [23, 25]. 
The logistics of PRO data collection have also been evaluated, finding high 
compliance rates using in-clinic tablet computer or paper questionnaire administration, 
between-visit web, or between-visit interactive voice response (IVR) automated telephone 
systems [8]. Investigative team effort at sites is minimal, and is generally restricted to 
training patients initially and reminding patients to report [26]. When between-visit 
reporting is employed, a central data management team can take over reminders and 
troubleshooting to unweight the local team. In prior trials, less than 1% of site data 
management time for any given trial has been consumed with these activities [24,27]. 
 In terms of analyses, there is ongoing debate about whether baseline symptom 
scores should be considered when reporting toxicities. Patients often enter clinical trials 
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with baseline symptoms related to their cancer, to prior treatments, or to comorbidities. 
Patient-reporting detects more of these baseline symptoms than clinicians. PROs 
therefore offer an opportunity to control for baseline (pre-existing) symptoms in 
assessments of toxicity, to identify those events most likely not to be preexisting. Indeed, it 
is common for regulatory agencies to evaluate adverse events using this approach, but 
less common for investigators when reporting trial results (e.g., when simple cumulative 
incidence numbers are provided in toxicity tables).  The approach to considering baseline 
symptoms is as follows: if a patient enters a trial with grade 2 nausea, and during the trial 
experienced grade 2 nausea, that toxicity would not be counted in an analysis of 
cumulative incidence of toxicities (i.e., coded as zero).  However, if the patient entered with 
grade 2 but then reported grade 3 during the trial, that would count as a grade 3. 
 Memory degradation is a concern, as recall of symptoms begins to fade within 
about a week [28]. Therefore, ideally weekly patient reporting will be employed during any 
period of active treatment in a trial, using electronic data capture whenever possible.  
However, data collection every 2 to 3 weeks can also be considered if necessary for a 
particular trial design, with an adjusted recall period (e.g., questionnaire every 2 weeks 
with recall period over the past two weeks), and with an understanding that some 
additional measurement error will be introduced [29].   
 One of the most substantial challenges in this area is reconciliation with investigator 
reports. As noted above, patient and clinician reports of symptomatic toxicities are often 
discrepant. There is no current consensus on the best approach to reconciliation, and 
several approaches have been suggested. One approach (Figure 3, panel A) is to share 
patient reports with investigators in real time at the point of care, so that investigators can 
make use of that information in the clinical management of the patient. In fact, this 
approach has been tested in prior clinical trials finding that patient-investigator agreement 
jumps to more than 90% [30]. Alternatively, patient and investigator reports can be 
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collected separately and reconciled at the time of analysis (Figure 3, panel B), with site 
queries and selection of the worst report of the two at any given time. If this approach is 
employed, ideally the baseline scores will be considered in the analysis as described 
above. A third potential approach (Figure 3, panel C) is to collect the information 
separately and not reconcile it, but simply report the patient and investigator reports side 
by side. Of these alternatives, the method with the greatest current interest combines 
options B and C, and involves sharing patient reports with investigators at the point of 
care, but also presenting patient and investigator reports separately. 
The final challenge relates to research culture and historical precedent. Patients 
have not traditionally self-reported toxicities, and there are some investigators who believe 
that patients might exaggerate or underestimate their own symptom burdens. This 
perspective is not consistent with current regulatory thinking or with empiric evidence [9, 
12-13]. 
 
PRO-CTCAE 
 In order to bring the patient perspective into toxicity reporting on oncology, in 2008 
the U.S. National Cancer Institute began developing a PRO version of the CTCAE [23]. 
The PRO-CTCAE was developed by a group of multidisciplinary collaborators under a 
contract to the NCI, with substantial input from the NCI and FDA. The PRO-CTCAE 
consists of a library of 78 toxicities mapped to the CTCAE, with up to three patient 
questions per toxicity. The patient questions were developed with extensive qualitative 
patient input including cognitive interviewing [5], as well as quantitative evaluation of 
measurement properties [31,32]. PRO-CTCAE items perform well overall, and equivalence 
has been found between paper, web, and automated telephone administration of these 
items. In addition to English, translations currently exist in Spanish, German, Danish, 
Italian, and Japanese, with additional translations in progress. 
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Recent evidence presented at the ISOQOL international meetings in 2014 and 2015 
report that the PRO-CTCAE better delineates symptomatic adverse events between study 
arms based on findings from multicentre cooperative group research, with statistically 
significant differences between study arms found for substantially more adverse events 
with patient reporting rather than clinician reporting [23]. Additionally, in evaluations in 
which patient-reported toxicities were shared with investigators, those investigators’ 
CTCAE reports were found to be more in line with patient reports [30, 33].  Moreover, in 
these evaluations, patient self-reports identified more baseline symptoms than clinics, 
enabling analyses of which symptoms were emergent during trials.  
The totality of this evidence suggests that although clinician CTCAE reporting has 
clinical value and is feasible, patient reporting brings greater precision, reliability, and 
validity to adverse symptom detection in clinical research [34].  Nonetheless, this is a 
nascent area and additional research and development work is warranted.  For example, 
evidence would be useful to inform the selection of PRO-CTCAE items for given 
populations and contexts; on methods for optimizing response rates particularly from hard-
to-reach patients; on how to optimally map PRO-CTCAE scores to CTCAE grades; and on 
how best to include both health-related quality of life (HRQL) tools and the PRO-CTCAE in 
a given trial.   
The PRO-CTCAE approach differs from traditional HRQL measurement, in several 
ways that have been outlined previously [8].  Briefly, there are over 100 toxicity questions 
in the item library for the PRO-CTCAE, and these items have been individually validated.  
The PRO-CTCAE includes questions on phenomena such as lower extremity edema and 
bed sores, which are generally not included in HRQL tools.  PRO-CTCAE questions are 
intended for frequent regular administration in trials, e.g., weekly, with analyses akin to 
standard AE assessment (i.e., the proportion of patients experiencing each maximum 
grade post-baseline expressed as a proportion) -- versus HRQL which generally includes 
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before-after assessments comparing means between study arms.  The purpose of the 
PRO-CTCAE is to assess symptomatic adverse events with greater precision than the 
CTCAE. Traditional HRQL tools are generally intended to assess treatment benefits 
between arms post baseline through global scores, or through the assessment of known 
disease-related symptoms.   
PRO-CTCAE is currently being used by numerous early adopters in clinical trials 
and observational studies, and can be requested through a Materials Transfer Agreement 
with the NCI. Interested parties can contact the NCI Outcomes Research Branch for 
further information (healthcaredelivery.cancer.gov/resource/outcomes.html).  Ideally, the 
PRO-CTCAE will be integrated widely into trials enabling organic development of methods 
for implementation and analysis within the research community, as occurred for the 
CTCAE with success in the past.   
 
Conclusions 
Direct reporting of symptomatic toxicities by patients brings the opportunity to improve the 
precision, reliability, and validity of symptom toxicity reporting in clinical research. This 
approach can generate information for use by future patients facing treatment decisions 
about the experiences of patients like them who participated in clinical trials. The U.S. 
National Cancer Institute recently developed a patient-reported outcomes version of the 
Common Terminology Criteria for Adverse Events (PRO-CTCAE), which offers a tangible 
approach to enhance the “patient-centeredness” of oncology clinical trials and drug 
development.   
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Key points 
 The report by cancer patients themselves is widely considered the gold 
standard for the assessment of symptoms, as patients are in the best 
position to comment on their own subjective experiences.  
 Published studies demonstrate that health professionals underestimate the 
incidence and severity of symptoms, when compared with the direct report by 
patients.  
 There is a growing movement toward the integration of patient-reported 
outcomes as part of routine toxicity data collection and reporting in clinical 
trials.  
 The U.S. National Cancer Institute recently developed a patient-reported 
outcomes version of the Common Terminology Criteria for Adverse Events 
(PRO-CTCAE) which may enhance the precision, reliability, and validity of 
symptomatic toxicity evaluation in cancer clinical research.  
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Table 1. Selected studies comparing patients’ and physicians’ reporting of toxicity associated with anti-cancer treatment. 
Author 
[year] 
Aim of the study Setting Instrument 
used for 
patients’ 
reporting 
Instrument 
used for 
physicians’ 
reporting 
Number 
of 
patients 
Number of 
institutions 
Main results 
Fellowes 
[2001]35 
To describe discrepancies 
between patient- 
reported and clinician-
recorded  symptom 
profiles 
Patients with 
early breast 
cancer 
receiving 
adjuvant 
hormonal 
treatment 
Interview  Not 
specified 
(Data 
reported in 
medical 
notes) 
72 10 Significant 
under-reporting 
in medical notes 
for many side 
effects.  
Fromme 
[2004]15 
To compare 
patients’reporting in QoL 
questionnaires with 
physicians reporting of 
toxicity 
Patients with 
advanced 
prostate 
cancer 
enrolled in a 
phase II trial 
EORTC QLQ-
C30 
 
NCI-CTC 
version 2.0 
37 2 Physician 
reporting was 
neither sensitive 
nor specific in 
detecting 
common 
chemotherapy 
adverse effects. 
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Basch 
[2006]16 
To compare the reporting 
of symptom severity 
reported by patients and 
clinicians  
Consecutive 
outpatients 
with lung or 
genitourinary 
cancers 
Modified 
CTCAE 
(questionnaire 
with 11 
common 
CTCAE 
symptoms, in a 
simplified 
language) 
 
CTCAE 400 1 For most 
symptoms, 
agreement 
between patient 
and clinician was 
high. Agreement 
was higher for 
symptoms that 
could be 
observable 
directly, such as 
vomiting and 
diarrhoea, than 
for more 
subjective 
symptoms, such 
as fatigue and 
dyspnoea. 
Basch 
[2009]7 
To compare how patient’s 
vs clinician’s reports relate 
to sentinel clinical events 
(deaths, emergency room) 
Lung cancer 
patients 
Modified 
CTCAE 
CTCAE 163 1 Patients 
generally 
reported 
symptoms 
earlier and more 
frequently than 
clinicians. 
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Cirillo 
[2009]17 
To compare symptoms 
collected by patient with 
symptoms recorded by 
either the clinician or the 
nurse 
Consecutive 
outpatients 
Modified 
CTCAE 
(questionnaire 
with 13 
common 
CTCAE 
symptoms, in a 
simplified 
language) 
 
CTCAE 
(Physicians 
/ nurses) 
85 1 With the 
exception of 
nausea (showing 
a good 
agreement with 
patients’ reports 
for both 
physicians and 
nurses), 
agreements 
between patients 
and nurses were 
generally 
stronger than 
those between 
patients and 
physicians 
Novello 
[2014]36 
To describe discrepancy 
between patients' and 
clinicians' perception of 
toxicities associated with 
targeted therapies for 
NSCLC 
Patients with 
advanced 
NSCLC 
treated with 
targeted 
drugs.  
Modified 
CTCAE 
(questionnaire 
with 7 common 
CTCAE 
symptoms, in a 
simplified 
language) 
 
CTCAE 
version 4.0 
133 7 Underestimation 
of toxicities by 
clinicians when 
compared with 
patients, with a 
greater 
difference for 
adverse events 
more strongly 
associated with 
daily life and 
QoL. 
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Gravis 
[2014]37 
To investigate differences 
between patients and 
clinicians reporting of 
treatment-related toxicity. 
Patients with 
advanced 
prostate 
cancer 
enrolled in a 
phase III trial 
Questionnaire 
about 26 
symptoms 
commonly 
associated with 
docetaxel and 
castration 
 
CTCAE 
version 3.0 
220 30 High rate of 
under-reporting by 
physicians, even 
for the most 
common and 
disturbing 
symptoms. 
Di Maio 
[2015]18 
To compare reporting by 
patients and physicians of 
six toxicities.  
Patients with 
early breast 
cancer or 
advanced 
lung cancer 
enrolled in 
three phase 
III trials 
EORTC QLQ- 
C30 (all 
patients), 
EORTC QLQ-
LC13 (lung 
cancer) 
EORTC QLQ-
BR23 (breast 
cancer) 
NCI-CTC 
version 2.0 
or 
CTCAE 
version 3.0 
1090 78   Agreement 
between patients 
and physicians 
was low for all 
toxicities. 
Toxicity rates 
reported by 
physicians were 
always lower 
than those 
reported by 
patients. 
Montemurro 
[2015]38 
To compare reporting by 
patients and physicians of 
10 chemotherapy-related 
side effects. 
Patients 
undergoing 
adjuvant 
chemotherapy 
for early 
breast cancer 
Italian 
translation of 
CTCAE v4.02 
CTCAE 
v4.02 
610 11 Frequency of 
chemotherapy-
related side 
effects  was 
systematically 
higher in 
patients’ reports 
than in 
physicians’ 
reports, as was 
the grade of 
severity. 
NSCLC: non-small cell lung cancer; QoL: quality of life; EORTC: European Organization for Research and Treatment of Cancer; QLQ: Quality of 
Life questionnaire; NCI-CTC: National Cancer Institute – Common Toxicity Criteria; CTCAE: Common Terminology Criteria for Adverse Events.  
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Table 2. Potential etiologies of clinician under-reporting of toxicities 
 Associated Risk of  
Sub-optimal Clinical 
Management of 
Toxicities 
Information about toxicity correctly acquired but not reported  
Pre-existing symptoms  Physicians could decide not to report those symptoms already 
present before treatment start, if considered unrelated to treatment 
but related to previous treatments or to disease itself. 
The symptom is correctly acquired, so risk of sub-optimal treatment 
is low.  
+/- 
Symptoms attributed to the 
disease itself 
Even if the symptoms were not present before treatment start, 
physicians could decide not to report those symptoms if considered 
related to disease itself. 
The symptom is correctly acquired, so risk of sub-optimal treatment 
is low.  
+/- 
Mild symptoms /  
Symptoms not needing 
intervention 
Physicians could pay less attention in reporting mild symptoms or 
those symptoms that do not need treatment modification 
(interruption, delay, dose reduction) or supportive treatments. 
Risk of sub-optimal treatment is present but low.  
+/- 
Toxicities correctly reported in 
patient’s file, but not in study case 
report form.  
Physicians could correctly report the occurrence of toxicity in 
patient’s clinical file, but not in study case report form.  
This under-reporting would affect the quality of study results and 
future communication between physicians and patients in clinical 
practice, but it will not necessarily affect the management of that 
patient in clinical practice.  
- 
Defect in communication between patient and physician  
Side effects largely expected  Physicians could be less likely to report a toxicity that is largely 
expected (and “routinely” managed) with the specific drug. 
The routine management could be the reason for under-reporting, so 
the risk of sub-optimal treatment is reasonably low.   
+/- 
Unusual side effects Physicians could be less likely to ask patients about the occurrence 
of a toxicity that is not commonly expected with the specific drug. 
+ 
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This would determine under-reporting as well as risk of sub-optimal 
management of toxicity.   
Toxicity not referred by patients If not part of a systematic assessment, toxicity will be reported only if 
specifically asked by the physician, or spontaneously reported by the 
patient.  
If the communication is defective, this will imply a substantial risk of 
sub-optimal management of toxicity. 
++ 
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Figure legends 
Figure 1. Relative under-reporting of toxicity by physicians, defined as the proportion of 
patients with toxicity reported in any of the cycles, but not reported at all by physician. Data 
are from 1090 patients with advanced lung cancer or early breast cancer, receiving 
anticancer treatment within 3 randomized controlled trials [based on data from Di Maio et 
al, J Clin Oncol 201521].  
 
Figure 2. Relative under-reporting by physicians of nausea, vomiting and diarrhea in the 
TORCH trial, comparing chemotherapy (cisplatin + gemcitabine) vs. erlotinib as first-line 
treatment of patients with advanced non-small cell lung cancer. These data suggest that 
physicians are more accurate in reporting those side effects that are expected with each 
specific treatment [based on data from Di Maio et al, J Clin Oncol 201521]. 
 
Figure 3. Possible modalities of reconciliation of patient’s and physician’s report of 
symptomatic toxicities. Panel A: patient reports are shared with investigators in real time 
during the visit. Panel B: patient and investigator reports are collected separately and 
reconciled at the time of analysis. Panel C: patient and investigator reports are collected 
and reported separately.  
 
